Iconic Therapeutics, Inc.

Biotechnology ResearchCalifornia, United States2-10 Employees

Iconic Therapeutics, Inc. is a clinical-stage biotechnology company focused on translating Tissue Factor biology into therapies for retinal diseases and cancer. The work emphasizes the involvement of Tissue Factor in angiogenesis and inflammation as a basis for new treatments. Based in South San Francisco, California, Iconic Therapeutics collaborates with leading researchers, clinicians, and advocacy groups to advance its programs. As a small organization, it pursues targeted therapies intended to address diseases driven by TF signaling. In October 2022, Endpoint Health acquired Iconic Therapeutics, enabling a precision immunology program linked to ICON4, which has been renamed EP004. This transfer of ownership accompanied continued development focused on TF-mediated signaling as the core of the program.

Sign up for free to view info

Email Format Employee directory